Cuproptosis is a form of cell death triggered by excess copper inside cells, and it works through a mechanism fundamentally different from the familiar ways cells die. Formally identified and named in a landmark 2022 study, it depends on mitochondrial respiration and targets specific proteins in the cell’s energy-production machinery.1PubMed Central. Copper induces cell death by targeting lipoylated TCA cycle proteins Since that discovery, researchers have connected cuproptosis to cancer, heart disease, neurodegeneration, genetic copper disorders, environmental toxicity, and even bacterial infections. The pathway is reshaping how scientists think about copper’s role in biology and opening up genuinely new therapeutic possibilities.
How Copper Kills Cells
Most people know copper as a trace mineral the body needs in small amounts. What makes cuproptosis distinctive is that it is not simply copper poisoning in the generic sense. When copper accumulates beyond what a cell can handle, it binds directly to proteins in the TCA cycle (the central hub of energy metabolism in mitochondria) that carry a chemical tag called a lipoyl group. Once copper latches onto these lipoylated proteins, they clump together abnormally. At the same time, the cell loses iron-sulfur cluster proteins, which are essential for dozens of enzymatic reactions. The combined effect, protein clumping plus iron-sulfur cluster depletion, creates a toxic stress that kills the cell.2PubMed Central. Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway
A protein called FDX1 plays a dual role in this process. It converts copper from one chemical form to another inside the mitochondria, releasing the copper so it can interact with those lipoylated targets. FDX1 also promotes the lipoylation process itself, essentially preparing the very proteins that copper will attack. Remove lipoylation from the equation and cells survive even when flooded with copper, which confirms that the lipoylated proteins are the critical vulnerability, not copper toxicity in some vague general sense.3PubMed Central. Deep Mutational Scanning of FDX1 Identifies Key Structural Determinants of Lipoylation and Cuproptosis
This mechanism is genuinely new. Cuproptosis does not resemble apoptosis (the orderly self-destruction cells normally use), necrosis (the messy rupture of damaged cells), or ferroptosis (the iron-driven death pathway identified about a decade ago). It is its own thing, with its own molecular triggers and its own dependencies.
Why Some Cells Are More Vulnerable Than Others
Because cuproptosis targets mitochondrial energy machinery, cells that rely heavily on mitochondria for their energy are far more susceptible. Cells running primarily on oxidative phosphorylation, the oxygen-dependent process in mitochondria, are exquisitely sensitive to copper overload.4Biomedicine & Pharmacotherapy. Cuproptosis: Current insights into its multifaceted role in disease, cancer, and translational/therapeutic opportunities Cells that have shifted to glycolysis, a less efficient but mitochondria-independent energy pathway, are much more resistant.
This metabolic split matters enormously for cancer. Many tumors, especially in low-oxygen environments, rely on glycolysis for energy. That glycolytic shift makes them naturally resistant to copper-based killing strategies. Glycolysis-dependent cancer cells are far less sensitive to copper-ionophore drugs than their respiration-dependent counterparts.5PubMed Central. Tumor glucose reprogramming suppresses cuproptosis: A review Researchers are already working on ways to force tumor cells back into a respiration-dependent state so that copper-based therapies become effective again. One experimental nanoplatform, for instance, generates oxygen locally within a tumor while simultaneously blocking glycolysis, locking the cancer cells into the metabolic state where cuproptosis can reach them.6PubMed. A Metabolic NanoLock strategy enhances cuproptosis in hypoxic tumors by enforcing mitochondrial respiration and suppressing glycolysis
How the Body Normally Manages Copper
Under healthy conditions, the body keeps copper levels in a tight range. A set of dedicated transport proteins handles this. CTR1 (also known as SLC31A1) is the main importer, bringing copper into cells. On the export side, two ATPase transporters, ATP7A and ATP7B, pump excess copper out of cells or shuttle it into compartments where it can be safely packaged and excreted.7PubMed Central. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression When this system works, intracellular copper stays well below the threshold that triggers cuproptosis.
Problems arise when something disrupts the balance. Oxidative stress, for example, can increase both CTR1 and ATP7A levels, and when copper import outpaces export, TCA-cycle-related protein aggregation and cell death follow. Blocking CTR1 under those conditions reduces both the protein clumping and the dying.8PubMed. SP1/CTR1-mediated oxidative stress-induced cuproptosis in intervertebral disc degeneration This means cuproptosis is not only about how much copper is around; it is about whether the cell’s transport machinery is functioning well enough to keep copper where it belongs.
Cancer Therapeutics Built Around Cuproptosis
The drug that has drawn the most attention in this space is elesclomol, a compound originally developed as an oxidative stress inducer. It turns out elesclomol’s cancer-killing ability depends heavily on its capacity to ferry copper ions into cells, a process now understood as cuproptosis induction.9PubMed Central. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy Copper toxicity kicks in once concentrations cross a critical threshold, and elesclomol exploits this by shuttling extracellular copper past the cell’s normal gatekeeping.10PubMed Central. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug
In pancreatic cancer, elesclomol combined with copper preferentially targets cancer stem cells while largely sparing normal cells.11Molecular Therapy. Nanoparticle-Mediated Cuproptosis Induction Combined with Standard Chemotherapy Targets Pancreatic Cancer Stem Cells That selectivity is significant because cancer stem cells are the subpopulation most responsible for treatment resistance and recurrence. If cuproptosis can reliably hit those cells, it addresses one of the most stubborn problems in oncology.
Nanotechnology is expanding the delivery options. Copper-based nanoparticles can be engineered to accumulate preferentially in tumors and release their copper payload in response to the tumor’s internal chemistry, such as elevated levels of reactive oxygen species or glutathione. In triple-negative breast cancer, one experimental nanoparticle simultaneously delivers copper alongside traditional chemotherapy drugs, triggering both cuproptosis and conventional cell death pathways while also suppressing the cell’s ability to pump copper back out.12PubMed. Copper-Based Composites Nanoparticles Improve Triple-Negative Breast Cancer Treatment with Induction of Apoptosis-Cuproptosis and Immune Activation More broadly, nanotechnology-based copper medicines have shown anticancer effects in both laboratory and animal studies, improving copper delivery and pharmacokinetics beyond what a bare copper compound can achieve.13PubMed Central. Copper-Based Nanomedicines for Cuproptosis-Mediated Effective Cancer Treatment
Cuproptosis Wakes Up the Immune System
One of the more exciting findings is that cuproptosis does not just kill tumor cells quietly. Dying tumor cells undergoing cuproptosis release molecular signals known as damage-associated molecular patterns, which activate dendritic cells and stimulate a broader immune response against the tumor.14Cell. Tumoral cuproptosis promotes antitumor immunity and synergizes with immunotherapy In other words, cuproptosis acts as a form of immunogenic cell death, turning a dead cancer cell into a beacon that draws the immune system’s attention.
This has immediate implications for immunotherapy. If cuproptosis-inducing drugs can be paired with checkpoint inhibitors or other immune-boosting treatments, the combination could be more effective than either approach alone. Researchers are exploring nanomedicine platforms specifically designed to trigger cuproptosis and simultaneously reshape the tumor’s immune environment, promoting immune cell infiltration and activating signaling pathways that amplify the body’s antitumor defenses.15PubMed Central. Cuproptosis-triggering nanomedicine boosts antitumor immunotherapy
Wilson Disease and Genetic Copper Overload
Wilson disease is a genetic condition where mutations in the ATP7B gene prevent the liver from properly excreting copper. Copper accumulates progressively, causing liver damage, neurological symptoms, and psychiatric problems. Researchers have now shown that cuproptosis is a central mechanism in this damage. In mouse models lacking functional ATP7B, liver tissue shows significantly elevated expression of key cuproptosis markers including FDX1, DLST, DLAT, and LIAS, all of which are proteins involved in the lipoylation and TCA cycle machinery that copper attacks.16PubMed Central. Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets
This reframes Wilson disease somewhat. It was always understood as copper toxicity, but “copper toxicity” was a vague label covering oxidative damage and general cellular stress. The cuproptosis framework gives a specific, targetable mechanism: lipoylated protein aggregation and iron-sulfur cluster loss in the mitochondria. That specificity opens the door to interventions beyond the traditional approach of chelation therapy, potentially including drugs that modulate lipoylation or protect iron-sulfur cluster proteins.
Neurodegeneration and Copper
Copper imbalances have been observed in Alzheimer’s, Parkinson’s, Huntington’s disease, and amyotrophic lateral sclerosis for years, but the mechanism connecting copper to neuronal death was always fuzzy. Cuproptosis provides a compelling molecular explanation: if copper accumulates in neurons and those neurons are metabolically active (as neurons tend to be, given their heavy reliance on mitochondria), the lipoylated-protein-aggregation pathway becomes a plausible route to cell death.17PubMed Central. Copper, Cuproptosis, and Neurodegenerative Diseases
In Alzheimer’s disease specifically, the link between copper overload and neuronal loss now has a mechanistic candidate rather than just a statistical correlation. The hallmark features of cuproptosis, lipoylated protein aggregation and iron-sulfur cluster disruption, provide a new framework for understanding how excess copper might drive the progressive neuron loss seen in the disease.18PubMed. Cuproptosis: mechanisms and links with Alzheimer’s disease The research is still in early stages and far from producing a treatment, but it is reorienting how some neurodegeneration researchers think about copper’s contribution to disease.
Heart Disease and Copper-Driven Damage
The heart is another organ with high metabolic demand, making cardiac cells theoretically vulnerable to cuproptosis. Evidence now links the pathway to several cardiovascular conditions, including heart failure, atherosclerosis, arrhythmias, and myocardial ischemia-reperfusion injury, the damage that occurs when blood flow returns to heart tissue after a blockage.19PubMed. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease Researchers have also found dysregulated cuproptosis markers in various types of cardiomyopathy, including dilated, hypertrophic, and diabetic cardiomyopathy, with mutations in the copper-export gene ATP7A contributing to pathological copper buildup and associated heart muscle damage.20PubMed Central. Cuproptosis and Cardiovascular Diseases: Mechanisms, Pathophysiology, and Therapeutic Strategies—A Narrative Review
One particularly concrete finding involves evolocumab, a drug already approved for lowering cholesterol via PCSK9 inhibition. In animal models of ischemia-reperfusion injury, evolocumab improved cardiac function and reduced cuproptosis markers. The mechanism involves blocking the interaction between PCSK9 and LIAS (one of the key lipoylation-related proteins copper targets), which inhibits the cuproptosis cascade in heart cells.21PubMed. Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes If this holds up in human trials, it would mean an existing drug has an entirely unanticipated second use.
Environmental and Dietary Copper Exposure
Cuproptosis is not only relevant to disease treatment. Environmental copper exposure is a real concern in occupational settings, contaminated water sources, and agricultural runoff. In pregnant mice, copper exposure at a dose described as reflecting real-world environmental levels was enough to trigger placental cuproptosis, leading to miscarriage or complete pregnancy loss. The full suite of cuproptosis features appeared: disrupted TCA cycle activity, protein aggregation, increased copper import, decreased copper export, and iron-sulfur cluster protein loss in placental tissue.22PubMed. Environmental copper exposure, placental cuproptosis, and miscarriage
Animal studies in other species reinforce the breadth of the problem. Excessive dietary copper in ducks caused dose-dependent intestinal damage and cuproptosis, with higher copper levels producing worse outcomes along a clear gradient.23PubMed. Copper-induced duodenal injury: Unveiling the dual role of cuproptosis and ferroptosis via the FDX1/GPX4 axis In zebrafish, dietary copper exposure triggered cuproptosis markers across multiple tissues and disrupted reproductive function through what researchers describe as a gut-gonadal axis, with cuproptosis in the intestine ultimately affecting the gonads.24PubMed. Dietary copper induces cuproptosis and disrupts the gut-gonadal axis in zebrafish (Danio rerio)
These findings do not mean dietary copper in normal amounts is dangerous. The body’s transport machinery handles typical intake without trouble. But they do suggest that cuproptosis may be a key pathway by which copper contamination in water, soil, or food causes harm, which could change how environmental regulators assess and manage copper exposure risks.
Copper Chelation as a Protective Strategy
If cuproptosis drives damage in copper-overload conditions, then removing excess copper should be protective, and the evidence supports this. Tetrathiomolybdate, a copper-chelating compound, has shown promise in multiple disease contexts. In a mouse model of kidney stones, it reduced copper accumulation, restored expression of cuproptosis-related proteins like FDX1 and ACO2, and improved kidney function as measured by drops in creatinine and blood urea nitrogen levels.25Asian Journal of Urology. Copper chelation by tetrathiomolybdate alleviates kidney damage from calcium oxalate stones by inhibiting cuproptosis and oxidative stress
The same chelator reduced cuproptosis markers and improved outcomes in a mouse model of periodontitis, where copper-driven death in macrophages (immune cells) contributed to the inflammatory destruction of gum tissue. Chelation dialed down the cuproptosis cascade and restored healthier cellular cleanup processes.26PubMed Central. Copper Chelation Therapy Attenuates Periodontitis Inflammation through the Cuproptosis/Autophagy/Lysosome Axis The dual-use nature of copper, a necessary nutrient and a potential toxin, means the therapeutic window for chelation requires care. Stripping out too much copper would create its own problems.
Copper Against Bacteria
The antimicrobial properties of copper have been recognized for centuries, but the cuproptosis framework adds a layer of mechanistic understanding. During bacterial infections, host cells actively accumulate copper in their interior, and this copper buildup enhances the cell’s defense against invading pathogens, including both intracellular bacteria (those living inside cells) and, perhaps surprisingly, extracellular bacteria as well.27PubMed Central. Copper regulates the host innate immune response against bacterial infection via activation of ALPK1 kinase
Bacteria lack mitochondria, so they cannot undergo cuproptosis in exactly the same way human cells do. Yet they are still vulnerable to a cuproptosis-like process. Copper binds to lipoylated proteins in bacteria much as it does in mitochondria, causing abnormal protein aggregation and iron-sulfur cluster loss that kills the microbe.28PubMed. Cuproptosis to Cuproptosis-Like: Therapeutic Strategies for Bacterial Infection This parallel has inspired interest in developing copper-based antimicrobial therapies, especially in the context of antibiotic resistance, where entirely new killing mechanisms are desperately needed.
An Evolutionarily Ancient Pathway
The fact that cuproptosis-like death occurs in organisms as different as human cells, zebrafish, ducks, bacteria, and single-celled protists suggests the pathway is extremely old. Studies in Tetrahymena, a ciliated microorganism used widely in laboratory research, have observed copper-induced metabolic dysfunction, oxidative stress, and mitochondrial fragmentation consistent with cuproptosis, indicating the mechanism predates the divergence of many major branches of life.29Water Biology and Security. Characterizing cuproptosis-like cell death in Tetrahymena thermophila: Metabolic dysfunction, oxidative stress, and mitochondrial fragmentation Species-specific adaptations exist, but the core vulnerability, copper binding to lipoylated metabolic proteins, appears deeply conserved.
Measuring Cuproptosis in the Lab
One practical challenge is that cuproptosis does not have a single simple biomarker. Because the pathway involves changes at multiple levels, researchers use a combination of techniques to confirm it is occurring: measuring intracellular copper content, checking for lipoylated protein aggregation, assessing iron-sulfur cluster protein levels, tracking TCA cycle metabolites, and evaluating mitochondrial respiration rates.30PubMed Central. Recent progress of methods for cuproptosis detection No single one of these is enough on its own, because each can also be altered by other forms of cellular stress. The field is still working toward a standardized, clinically practical detection method, which will be important if cuproptosis-based therapies ever reach the clinic and doctors need to confirm a treatment is working through its intended mechanism.
For now, the reliance on multi-method verification keeps the science honest but limits how quickly cuproptosis research can move from the bench to patient care. Whoever develops a reliable, fast assay for cuproptosis will likely accelerate the entire field.